Baylor University Medical Center-ko ikertzaileekin lankidetzan egindako argitalpenak (1)

2017

  1. Secukinumab demonstrates greater sustained improvements in daily activities and personal relationships than ustekinumab in patients with moderate-to-severe plaque psoriasis: 52-week results from the CLEAR study

    Journal of the European Academy of Dermatology and Venereology, Vol. 31, Núm. 10, pp. 1693-1699